Skip to main content

Alzheimer’s Disease May 2022 – Is There Anything New?

The last time Doc Gumshoe surveyed the Alzheimer’s landscape, the most prominent feature was the FDA’s approval – misguided, I thought – of Biogen’s Aduhelm (aducanumab) and the consequences this would have for everybody’s Medicare B premium. Sure enough, on November 12, 2021, the Centers for Medicare and Medicaid Services (CMS) confirmed the prediction that […]
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.